JP Morgan Chase
GNMX

JP Morgan Chase’s Aevi Genomic Medicine Inc GNMX Stock Holding History

JP Morgan Chase’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-101,118
Closed -$203K – 5797
2018
Q1 		$203K Buy
101,118
+99,018
+4,715% +$186K ﹤0.01% 4368
2017
Q4 		$3K Sell
2,100
-18,760
-90% -$25.6K ﹤0.01% 5360
2017
Q3 		$26K Buy
20,860
+4,200
+25% +$5.37K ﹤0.01% 4607
2017
Q2 		$22K Buy
16,660
+510
+3% +$737 ﹤0.01% 4526
2017
Q1 		$30K Sell
16,150
-8,713
-35% -$39.4K ﹤0.01% 4645
2016
Q4 		$129K Buy
+24,863
New +$131K ﹤0.01% 4326

Other funds holding GNMX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

JP Morgan Chase's GNMX Position: Q2 2018 in Review

JP Morgan Chase sold out of Aevi Genomic Medicine Inc (GNMX) in Q2 2018, closing a stake of 101,118 shares — an estimated $203K sold.

JP Morgan Chase first reported a position in GNMX in Q4 2016 and held it in 6 quarters. The position peaked at $203K in Q1 2018. 40 funds tracked by Wall St. Rank hold GNMX as of Q2 2018.

  • JP Morgan Chase reported no remaining Aevi Genomic Medicine Inc position as of Q2 2018 after selling out during the quarter.
  • JP Morgan Chase sold 101,118 Aevi Genomic Medicine Inc shares in Q2 2018, an estimated $203K.
  • JP Morgan Chase first reported a position in Aevi Genomic Medicine Inc in Q4 2016 and held it in 6 quarters.
  • JP Morgan Chase's Aevi Genomic Medicine Inc position peaked at $203K in Q1 2018.
  • 40 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q2 2018.

Based on JP Morgan Chase's 13F filing for Q2 2018, filed 14 Aug 2018.